Audentes Therapeutics
San Francisco
About Audentes Therapeutics
Audentes Therapeutics doing business as Astellas Gene Therapies, Inc. is a biotechnology company that serves as the Gene Therapy Center of Excellence. The company is divided into three divisions that specialize in gene therapy research, including technical operations, medical and development, and future commercialization of gene therapy programs. Audentes Therapeutics was acquired by Astellas Pharma on January 15, 2020.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 251 – 500
- Estimated revenue: $10K – $50K
- Total funding: $744.7M
- Funding stage: M&A
- Last round: Post-IPO Equity (Oct 2018)
- Ticker: nasdaq:BOLD
- Website: audentestx.com
- Phone: +1 (415) 638-6556
Industries & Categories
Biotechnology, Genetics, Health Care, Health Diagnostics
Social Profiles
Canonical: https://fsome.com/organization/audentes-therapeutics-95075 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.